logo
TakedaPresentsNewDataShowingMezagitamab(TAK-079)SustainedEffectonKidneyFunction18MonthsAfterTreatmentinPrimaryIgANephropathy
===2025/11/10 15:13:58===
ith any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this pr
=*=*=*=*=*=
当前为第10/15页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页